A Covalent, Allele-Specific Monovalent Degrader for the Treatment of NASH
Time: 12:15 pm
day: Conference Day Two
Details:
- Phenotypic screen points to a degrader; MoA determination and target deconvolution
- Chembio and covalency leveraged to identify a clinical candidate
- Carrying and de-risking covalency from discovery to clinical development of asset in FIH
